EUVIMEDEUVIMED entdecken
Crossref

Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative

Zikun Wang iD, Lawrence S Phillips, Thomas E Rohan, Gloria Y F Ho, Aladdin H Shadyab, Aurelian Bidulescu, Charles N Rudick, Kathy Pan, Zhongxue Chen, Juhua Luo iD

International Journal of Cancer · 15.04.2023 · 152 (8) · 1556-1569

DOI: 10.1002/ijc.34376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 07.12.2022. Verfasst von Zikun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA. Hauptthemen laut MEDLINE: Metformin, Lymphoma, Non-Hodgkin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidemiologic evidence is limited about associations between T2DM, metformin, and the risk of non‐Hodgkin's lymphoma (NHL). We aimed to examine associations between T2DM, metformin, and the risk of NHL in the Women's Health Initiative (WHI) Study. Information on T2DM status (diabetes status/types of antidiabetic drug use/diabetes duration) from study enrollment and during follow‐up were assessed. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate associations of T2DM status with risks of overall NHL and its three major subtypes [diffuse large B‐cell lymphoma (DLBCL, n = 476), follicular lymphoma (FL, n = 301) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, n = 136)] based on multivariable‐adjusted Cox proportional hazards models. During a median follow‐up of 18.86 years (range, 0.01‐25.13; SD ± 6.55), a total of 1637 women developed NHL among 147 885 postmenopausal women. Women with T2DM and with self‐reported oral medication use had 38% and 55% higher risk of DLBCL, respectively [multivariable‐adjusted model HR = 1.38, 95% CI (1.06‐1.81) and HR = 1.55, 95% CI (1.16‐2.06)] compared to the reference group (nondiabetics/untreated diabetes). Risks of NHL and DLBCL [multivariable‐adjusted model: HR = 1.28, 95% CI (1.06‐1.54) and HR = 1.56, 95% CI (1.13‐2.14), respectively] were significantly higher in associations with relatively short duration (≤7 years) of diabetes, compared to reference group. Additionally, an increased risk of DLBCL [HR = 1.76, 95% CI (1.13‐2.75)] was found in metformin users compared to the reference group. Postmenopausal women who had T2DM, who were oral antidiabetic drug users, especially metformin, and who had a shorter diabetes duration may have higher risks of DLBCL. Further well‐designed research is needed to confirm our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminLymphoma, Non-HodgkinDiabetes Mellitus, Type 2FemaleHumansProspective StudiesRisk FactorsPostmenopauseWomen's HealthCohort StudiesHypoglycemic Agents

Stichwörter der Autor:innen

antidiabetic medicationsdiffuse large B-cell lymphomaduration of diabetes mellituspopulation-based studytype 2 diabetes mellitus

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA.
  • Atlanta VA Medical Center, Decatur, Georgia, USA.
  • Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • Department of Pharmacology and Toxicology, Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, Indiana, USA.

ORCID-Profile: Zikun Wang, Juhua Luo

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Wang, Z., Phillips, L. S., Rohan, T. E., Ho, G. Y. F., Shadyab, A. H., Bidulescu, A., Rudick, C. N., Pan, K., Chen, Z., & Luo, J. (2023). Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative. International Journal of Cancer, 152(8), 1556-1569. https://doi.org/10.1002/ijc.34376

Vancouver

Wang Z, Phillips LS, Rohan TE, Ho GYF, Shadyab AH, Bidulescu A, et al. Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative. International Journal of Cancer. 2023;152(8):1556-1569. doi:10.1002/ijc.34376

BibTeX
@article{Wang2023,
  author = {Wang, Zikun and Phillips, Lawrence S and Rohan, Thomas E and Ho, Gloria Y F and Shadyab, Aladdin H and Bidulescu, Aurelian and Rudick, Charles N and Pan, Kathy and Chen, Zhongxue and Luo, Juhua},
  title = {Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {8},
  pages = {1556--1569},
  doi = {10.1002/ijc.34376}
}
Kostenlos starten →